Phase
Condition
Neutropenia
Treatment
N/AClinical Study ID
Ages 18-120 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Be 18 years of age or older.
Receiving treatment in inpatient oncology services at Wake Forest University BaptistMedical Center
Receiving chemotherapy or have received chemotherapy within the past 2 weeks
Seropositive herpes simplex virus (HSV)-1 or HSV-2 immunoglobulin antibody assay
Creatinine clearance ≥ 50 mL/min
Intravenous acyclovir sodium therapy is deemed necessary by the physician based uponclinical judgement (i.e., mucositis, vomiting, decreased GI absorption)
Exclusion
Exclusion Criteria:
Pregnant or nursing
Hypersensitivity to acyclovir sodium
High tumor burden (i.e., WBC > 50,000/mm^3 at admission)
Neutropenic, defined as one of the following:
ANC < 500/mm^3
ANC < 1,000/mm^3 with a predicted decrease to 500/mm^3
Active HSV infection, as evidenced by any of the following:
Positive HSV cultures
Oral lesions
Receiving 5 mg/kg acyclovir sodium every 8 hours
Study Design
Study Description
Connect with a study center
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina 27157-1096
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.